Business Wire

Data Security Innovator, Secure Channels, Chooses Thales to Provide Key Management and Software Licensing Platform For IoT Security Solution

22.1.2020 10:00:00 EET | Business Wire | Press release

Share

Thales has announced its encryption key management and software licencing platforms have been chosen by Secure Channels to protect its quantum-resilient encryption keys for its IoT-enabled devices. By using Thales’ key management platform, both companies’ customers will benefit from increased data protection no matter the connected device, even if there is no current security protection in place. In addition, Thales’ software licensing platform will enable easy access to Secure Channels’ cybersecurity software technology for customers and manufacturers, thus ensuring all IoT devices can be protected easily either at source or retrospectively.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005189/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Thales)

“Thales’s Sentinel Entitlement Management Software has enabled the first generation of truly secure connected devices,” said Secure Channels Chief Executive Officer Richard Blech. “With the vast increase in the number of connected devices hitting the market recently, many are landing in the hands of users without any real protection. The Sentinel EMS tool has enabled our encryption to be launched, managed and distributed within very secure offline environments in addition to cloud-based connected devices protecting the multitude of data flowing within them.”

Thales’s enterprise key management platform provides secure storage for the larger-than-average encryption keys required for long-term data protection. Secure Channels’ XOTIC strong cryptosystem ranges in encryption strengths from 512-bit to more than 8,000-bit protection. XOTIC’s “bottom floor” is twice as strong as the prevalent 256-bit encryption that will have questionable efficacy against post-quantum attacks. The combined key management and evolved-encryption solution gives customers highly secure, archive-level data protection across each IoT-enabled device they develop and own.

Manufacturers are challenged with protecting user data transmitted and stored in devices with power, bandwidth and CPU constraints that preclude the use of adequate encryption. As the demand for the rate of connected devices has increased, this has resulted in a sub-optimal security that leaves the data vulnerable to malicious third parties. XOTIC’s ultralight-weight footprint and high-speed performance provide manufacturers a strong encryption solution that fits in their devices while preserving responsiveness.

The collaboration gives manufacturers and customers improved access to Secure Channels’ XOTIC via Thales’ software licensing platform, Sentinel EMS. This platform provides security benefits to manufacturers of devices that transmit sensitive user data, as increasing data privacy regulations assign liability and penalties for a failure to provide reasonable security protection.

The threat of quantum computing is something that could dominate the business world for years to come as the fear of its computing power is likely to grow,” said Sebastien Cano, senior vice president for cloud protection and licensing activities at Thales. “We’re delighted to partner with Secure Channels to put these fears to bed from now on by protecting any connected device no matter the level of protection they already have or don’t have, and enable companies to focus on innovating and progressing without a lingering doubt over the long-term futures of their sensitive data. It’s also vital that security is seen as easy to use and easily accessible, as provided by our licensing platform.”

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gem alto).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments

PLEASE VISIT

Thales Group
Security
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thales, Media Relations
Security
Constance Arnoux
+33 (0)1 57 77 91 58
constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release

Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye